Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(101)
•••
Comment by Quentin30on Jan 12, 2024 4:19pm
106 Views
Post# 35824369

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 monthsNo Azzak, not Phase III ready until the protocol is approved, and the sites ready to recruit... This has not happened yet... so Phase III remains aspirational...

We've had 3 CMOs over the past 6 and a half years... and Coffey has been stating, we're Phase III ready all that time... hmm, you could argue that since we recieved a SPA from FDA to conduct a 450 patient study in mBC with a doublet  vs Paclitaxel alone that we are indeed ready... but ONCY tells us they are waiting fro ADACs to fail, and for more Bracelet-1 data. Why wait, we have the green light already...

But the problem with this trial is that it STILL includes Chemo, and is NOT a cure... Maybe that's why partners aren't interested.

Hardly garbage
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities